Clinical Trial Update: A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing dinaciclib to ofatumumab in patients with refractory chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Dinaciclib (dinaciclib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Status: COMPLETED